Martina Molsbergen

Ms.Molsbergen has +35 years of business development, marketing, and entrepreneurialexperience including 26 years of business development experience inbiotherapeutics and antibodies.  She hasproven corporate development strategy and leadership experience within largeand small company settings.  She is theCEO of C14 Consulting Group, apremier provider of strategic business strategy and licensing and dealnegotiation. She was the Vice President ofBusiness Development (PER. C6 Licensing) at Crucell Holland BV.  In this capacity she has established thePER.C6 manufacturing technology platform for therapeutic antibodies andproteins, manages global business development team as well as the joint venturewith DSM Biologics.  She has brought morethan twenty new licensing opportunities.

Previouslyas the Vice President of Business Development, Ms. Molsbergen played a key rolein establishing and building BioWa, Inc., a novel antibody engineering platformcompany as a subsidiary of a Japanese company Kyowa Hakko Kogyo (KHK).  In three years of business activity, shesuccessfully negotiated more than 15 deals valued at over $2.5 B in futuremilestone payments and royalties with leading antibody and biopharma companies.  She participated with KHK to identify newinvestment opportunities, and strategic planning for internal product pipelinedevelopment.  The efforts led to thecreation of market value of BioWa to reach over $1B in three years. Ms.Molsbergen received two President’s awards for her achievements.  She has been featured in Nikkei Magazine forher business deal achievements with and on behalf of Japanese companies (May2007, June 2012).

Inaddition, Ms. Molsbergen has 12+ years of business development experience insmall molecule pharmaceutical and manufacturing companies including Patheon,Watson Pharmaceuticals and FMC Corporation. She has a B.S. in Chemical Engineering from Drexel University.